HC Wainwright & Co. Reiterates Buy on Lyell Immunopharma, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Lyell Immunopharma (NASDAQ:LYEL) with a maintained price target of $6.

May 07, 2024 | 10:46 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Mitchell Kapoor reiterates a Buy rating on Lyell Immunopharma with a $6 price target.
The reiteration of a Buy rating and maintenance of a $6 price target by a reputable analyst like Mitchell Kapoor could positively influence investor sentiment towards LYEL. This endorsement reaffirms the analyst's confidence in the company's prospects, potentially leading to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100